<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2025-2-52-55</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-4255</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕВРОЛОГИЯ И ПСИХИАТРИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROLOGY AND PSYCHIATRY</subject></subj-group></article-categories><title-group><article-title>Вальпроевая кислота: историческая справка  и перспективы применения в ургентной  психиатрической практике</article-title><trans-title-group xml:lang="en"><trans-title>Valproic acid: historical background and prospects   for use in urgent psychiatric practice</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2972-235X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козловский</surname><given-names>В. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlovsky</surname><given-names>V. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Козловский Владимир Леонидович, ведущий научный сотрудник; врач клинический фармаколог</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p> Kozlovsky Vladimir L., leading researcher; clinical pharmacologist</p><p>St. Petersburg</p></bio><email xlink:type="simple">kvl1958@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-9638-1468</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Забродина</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zbrodina</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Забродина Алина Сергеевна, врач-психиатр</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p> Zbrodina Alina S., psychiatrist</p><p>St. Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В. М. Бехтерева» Минздрава России; СПб ГКУЗ «Городская психиатрическая больница № 6 (стационар с диспансером)»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The St. Petersburg Bekhterev Psychoneurological Research Institute; City psychiatric hospital No 6</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>СПб ГКУЗ «Городская психиатрическая больница № 6 (стационар с диспансером)»Санкт-Петербург</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City psychiatric hospital No 6</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>03</month><year>2025</year></pub-date><volume>0</volume><issue>2</issue><issue-title>«Неврология и психиатрия» (1)</issue-title><fpage>52</fpage><lpage>55</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Козловский В.Л., Забродина А.С., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Козловский В.Л., Забродина А.С.</copyright-holder><copyright-holder xml:lang="en">Kozlovsky V.L., Zbrodina A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/4255">https://www.med-alphabet.com/jour/article/view/4255</self-uri><abstract><p>Расширение показаний к применению вальпроевой кислоты (ВК) отмечено с конца ХХ в. С одной стороны, это обусловлено фармакодинамикой препарата и благоприятным профилем его клинического действия, а с другой – появлением современных лекарственных форм, определяющих удобство применения. По аналогии с карбамазепином терапевтическая активность ВК стала изучаться при психических расстройствах. Наряду с тимостабилизирующим действием, подобным литию, ВК начали применять для терапии не только аффективных колебаний, но и профилактики вторичных обострений эндогенной прогредиентной патологии шизофренического спектра. С разработкой концепции, основывающейся на взаимодействии нейрональных сетей, при отсутствии первичного влияния на медиаторный гомеостаз перспективы применения ВК в психиатрии не исчерпываются сказанным. Благодаря появлению лекарственной формы для парентерального введения перспективы применения ВК при терапии ургентных состояний имеют значительные перспективы применения в психиатрической практике.</p></abstract><trans-abstract xml:lang="en"><p>The expansion of indications for the use of valproic acid (VK) has been noted since the end of the 20th century. On the one hand, this is due to the pharmacodynamics of the drug and the favorable profile of its clinical action, and on the other hand, the emergence of modern dosage forms that determine the ease of use. By analogy with carbamazepine, the therapeutic activity of VK began to be studied in mental disorders. Along with the thymostabilizing effect similar to lithium, VK began to be used for the treatment of not only affective fluctuations, but also for the prevention of secondary exacerbations of endogenous progressive pathology of the schizophrenia spectrum. With the development of a concept based on the interaction of neural networks, in the absence of a primary effect on mediator homeostasis, the prospects for the use of VK in psychiatry are not limited to what has been said. Due to the emergence of a dosage form for parenteral administration, the prospects for the use of VK in the treatment of urgent conditions have significant prospects for application in psychiatric practice. Key words: valproic acid (VA), pharmacodynamics, neural networks, neuronal excitability, mental pathology, neurometabolic action.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>вальпроевая кислота (ВК)</kwd><kwd>фармакодинамика</kwd><kwd>нейрональные сети</kwd><kwd>возбудимость нейронов</kwd><kwd>психическая патология</kwd><kwd>нейрометаболическое действие</kwd></kwd-group><kwd-group xml:lang="en"><kwd>valproic acid (VA)</kwd><kwd>pharmacodynamics</kwd><kwd>neuronal networks</kwd><kwd>neuronal excitability</kwd><kwd>mental pathology</kwd><kwd>neurometabolic action</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Карпова В. И., Пылаева О. А., Мухин К. Ю., Петрухин А. С. Вальпроевая кислота и ее соли – от истории открытия до клинической практики (исторический очерк). Рус. жур. дет. невр. 2011; VI (3): 36–46.</mixed-citation><mixed-citation xml:lang="en">Karpova V. I., Pylaeva O. A., Mukhin K. Yu., Petruhin A. S. Valproic acid and its salts – from the history of discovery to clinical practice (historical essay). Rus. jour. det. nevr. 2011; VI (3): 36–46. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bruni J, Wilder BJ. Valproic acid. Review of a new antiepileptic drug. Arch Neurol. 1979 Jul;36(7):393–8. DOI: 10.1001/archneur.1979.00500430023002. PMID: 110294.</mixed-citation><mixed-citation xml:lang="en">Bruni J, Wilder BJ. Valproic acid. Review of a new antiepileptic drug. Arch Neurol. 1979 Jul;36(7):393–8. DOI: 10.1001/archneur.1979.00500430023002. PMID: 110294.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Löscher W, Frey HH. On the mechanism of action of valproid acid.</mixed-citation><mixed-citation xml:lang="en">Löscher W, Frey HH. On the mechanism of action of valproid acid.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Post RM, Weiss SR, Chuang DM. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J. Clin. Psychopharmacol. 1992 Feb; 12 (1 Suppl): 23S-35S. DOI: 10.1097/00004714-199202001-00005. PMID: 1541715.</mixed-citation><mixed-citation xml:lang="en">Post RM, Weiss SR, Chuang DM. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J. Clin. Psychopharmacol. 1992 Feb; 12 (1 Suppl): 23S-35S. DOI: 10.1097/00004714-199202001-00005. PMID: 1541715.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Grunze HC. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci. 2008; 10 (1): 77–89. DOI: 10.31887/DCNS.2008.10.1/hcrgrunze. PMID: 18472486 Arzneimittelforschung. 1977; 27 (5): 1081–2. PMID: 328017.</mixed-citation><mixed-citation xml:lang="en">Grunze HC. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci. 2008; 10 (1): 77–89. DOI: 10.31887/DCNS.2008.10.1/hcrgrunze. PMID: 18472486 Arzneimittelforschung. 1977; 27 (5): 1081–2. PMID: 328017.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Battistin L, Varotto M, Berlese G, Roman G. Effects of some anticonvulsant drugs on brain GABA level and GAD and GABA-T activities. Neurochem Res. 1984 Feb; 9 (2): 225–31. DOI: 10.1007/BF00964170. PMID: 6429560.</mixed-citation><mixed-citation xml:lang="en">Battistin L, Varotto M, Berlese G, Roman G. Effects of some anticonvulsant drugs on brain GABA level and GAD and GABA-T activities. Neurochem Res. 1984 Feb; 9 (2): 225–31. DOI: 10.1007/BF00964170. PMID: 6429560.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett. 1990 Aug 14; 116 (1–2): 233–8. DOI: 10.1016/0304–3940(90)90416-7. PMID: 2175404.</mixed-citation><mixed-citation xml:lang="en">Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett. 1990 Aug 14; 116 (1–2): 233–8. DOI: 10.1016/0304–3940(90)90416-7. PMID: 2175404.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zona C, Avoli M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture. Exp Brain Res. 1990; 81 (2): 313–7. DOI: 10.1007/BF00228121. PMID: 2168843.</mixed-citation><mixed-citation xml:lang="en">Zona C, Avoli M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture. Exp Brain Res. 1990; 81 (2): 313–7. DOI: 10.1007/BF00228121. PMID: 2168843.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Карлов В. А., Лебедева А. В., Степаненко А. Ю., Рудакова И. Г., Власов П. Н., Липатова Л. В., Попугаев К. А., Головтеев А. Л., Гехт А. Б. Возможности при менения внутривенных форм противоэпилептических препаратов при эпилептических приступах. Журнал неврологии и психиатрии. 2014; 4 (2): 66–75.</mixed-citation><mixed-citation xml:lang="en">Karlov V. A., Lebedeva A. V., Stepanenko A. Yu., Rudakova I. G., Vlasov P. N., Lipatova L. V., Popugaev K. A., Golovteev A. L., Gekht A. B. Possibilities of using intravenous forms of antiepileptic drugs in epileptic seizures. Journal of Neurology and Psychiatry. 2014; 4 (2): 66–75. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Veitch K, Van Hoof F. In vitro effects of eight-carbon fatty acids on oxidations in rat liver mitochondria. Biochem Pharmacol. 1990 Nov 1; 40 (9): 2153–9. DOI: 10.1016/0006–2952(90)90248-j. PMID: 2242043.</mixed-citation><mixed-citation xml:lang="en">Veitch K, Van Hoof F. In vitro effects of eight-carbon fatty acids on oxidations in rat liver mitochondria. Biochem Pharmacol. 1990 Nov 1; 40 (9): 2153–9. DOI: 10.1016/0006–2952(90)90248-j. PMID: 2242043.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rumbach L, Cremel G, Marescaux C, Warter JM, Waksman A. Succinate transport inhibition by valproate in rat renal mitochondria. Eur. J. Pharmacol. 1989 May 30; 164 (3): 577–81. DOI: 10.1016/0014-2999(89)90267-7. PMID: 2504612.</mixed-citation><mixed-citation xml:lang="en">Rumbach L, Cremel G, Marescaux C, Warter JM, Waksman A. Succinate transport inhibition by valproate in rat renal mitochondria. Eur. J. Pharmacol. 1989 May 30; 164 (3): 577–81. DOI: 10.1016/0014-2999(89)90267-7. PMID: 2504612.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Strolin Benedetti M, Rumigny JF, Dostert P. Mechanisms of action and biochemical toxicology of valproic acid]. Encephale. 1984; 10 (4): 177–88. PMID: 6094147.</mixed-citation><mixed-citation xml:lang="en">Strolin Benedetti M, Rumigny JF, Dostert P. Mechanisms of action and biochemical toxicology of valproic acid]. Encephale. 1984; 10 (4): 177–88. PMID: 6094147.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Shnayder NA, Grechkina VV, Khasanova AK, Bochanova EN, Dontceva EA, Petrova MM, Asadullin AR, Shipulin GA, Altynbekov KS, Al-Zamil M, Nasyrova RF. Therapeutic and Toxic Effects of Valproic Acid Metabolites. Metabolites. 2023 Jan 16; 13 (1): 134. DOI: 10.3390/metabo13010134. PMID: 36677060.</mixed-citation><mixed-citation xml:lang="en">Shnayder NA, Grechkina VV, Khasanova AK, Bochanova EN, Dontceva EA, Petrova MM, Asadullin AR, Shipulin GA, Altynbekov KS, Al-Zamil M, Nasyrova RF. Therapeutic and Toxic Effects of Valproic Acid Metabolites. Metabolites. 2023 Jan 16; 13 (1): 134. DOI: 10.3390/metabo13010134. PMID: 36677060.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jia L, Verkerk AO, Tan HL. The Anti-Epileptic Drugs Lamotrigine and Valproic Acid Reduce the Cardiac Sodium Current. Biomedicines. 2023 Feb 7; 11 (2): 477. DOI: 10.3390/biomedicines11020477. PMID: 36831014.</mixed-citation><mixed-citation xml:lang="en">Jia L, Verkerk AO, Tan HL. The Anti-Epileptic Drugs Lamotrigine and Valproic Acid Reduce the Cardiac Sodium Current. Biomedicines. 2023 Feb 7; 11 (2): 477. DOI: 10.3390/biomedicines11020477. PMID: 36831014.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wolking S, Moreau C, Nies AT, Schaeffeler E, McCormack M, Auce P, Avbersek A, Becker F, Krenn M, Møller RS, Nikanorova M, Weber YG, Weckhuysen S, Cavalleri GL, Delanty N, Depondt C, Johnson MR, Koeleman BPC, Kunz WS, Marson AG, Sander JW, Sills GJ, Striano P, Zara F, Zimprich F, Schwab M, Krause R, Sisodiya SM, Cossette P, Girard SL, Lerche H; EpiPGX. Testing association of rare genetic variants with resistance to three common antiseizure medications. Consortium. Epilepsia. 2020 Apr; 61 (4): 657–666. DOI: 10.1111/epi.16467. Epub 2020 Mar 6. PMID: 32141622.</mixed-citation><mixed-citation xml:lang="en">Wolking S, Moreau C, Nies AT, Schaeffeler E, McCormack M, Auce P, Avbersek A, Becker F, Krenn M, Møller RS, Nikanorova M, Weber YG, Weckhuysen S, Cavalleri GL, Delanty N, Depondt C, Johnson MR, Koeleman BPC, Kunz WS, Marson AG, Sander JW, Sills GJ, Striano P, Zara F, Zimprich F, Schwab M, Krause R, Sisodiya SM, Cossette P, Girard SL, Lerche H; EpiPGX. Testing association of rare genetic variants with resistance to three common antiseizure medications. Consortium. Epilepsia. 2020 Apr; 61 (4): 657–666. DOI: 10.1111/epi.16467. Epub 2020 Mar 6. PMID: 32141622.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Reynolds GP, Fachim HA. Does DNA methylation influence the effects of psychiatric drugs? Epigenomics. 2016 Mar; 8 (3): 309–12. DOI: 10.2217/epi.15.116. Epub 2016 Feb 26. PMID: 26918935.</mixed-citation><mixed-citation xml:lang="en">Reynolds GP, Fachim HA. Does DNA methylation influence the effects of psychiatric drugs? Epigenomics. 2016 Mar; 8 (3): 309–12. DOI: 10.2217/epi.15.116. Epub 2016 Feb 26. PMID: 26918935.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Higgins GA, Georgoff P, Nikolian V, Allyn-Feuer A, Pauls B, Higgins R, Athey BD, Alam HE. Network Reconstruction Reveals that Valproic Acid Activates Neurogenic Transcriptional Programs in Adult Brain Following Traumatic Injury. Pharm Res. 2017 Aug; 34 (8): 1658–1672. DOI: 10.1007/s11095-017-2130-6. Epub 2017 Mar 7. PMID: 28271248.</mixed-citation><mixed-citation xml:lang="en">Higgins GA, Georgoff P, Nikolian V, Allyn-Feuer A, Pauls B, Higgins R, Athey BD, Alam HE. Network Reconstruction Reveals that Valproic Acid Activates Neurogenic Transcriptional Programs in Adult Brain Following Traumatic Injury. Pharm Res. 2017 Aug; 34 (8): 1658–1672. DOI: 10.1007/s11095-017-2130-6. Epub 2017 Mar 7. PMID: 28271248.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kandel ER. Eric Kandel: a life in learning and memory. Drug Discov Today. 2005 Mar 1; 10 (5): 302–4. DOI: 10.1016/S 1359-6446(04)03331-8. PMID: 15749276.</mixed-citation><mixed-citation xml:lang="en">Kandel ER. Eric Kandel: a life in learning and memory. Drug Discov Today. 2005 Mar 1; 10 (5): 302–4. DOI: 10.1016/S 1359-6446(04)03331-8. PMID: 15749276.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Jones MW. Errant ensembles: dysfunctional neuronal network dynamics in schizophrenia. Biochem Soc Trans. 2010 Apr; 38 (2): 516–21. DOI: 10.1042/BST0380516. PMID: 20298213.</mixed-citation><mixed-citation xml:lang="en">Jones MW. Errant ensembles: dysfunctional neuronal network dynamics in schizophrenia. Biochem Soc Trans. 2010 Apr; 38 (2): 516–21. DOI: 10.1042/BST0380516. PMID: 20298213.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Pototskiy E, Dellinger JR, Bumgarner S, Patel J, Sherrerd-Smith W, Musto AE.Brain injuries can set up an epileptogenic neuronal network. Neurosci Biobehav Rev. 2021 Oct; 129: 351–366. DOI: 10.1016/j.neubiorev.2021.08.003. Epub 2021 Aug 9. PMID: 34384843.</mixed-citation><mixed-citation xml:lang="en">Pototskiy E, Dellinger JR, Bumgarner S, Patel J, Sherrerd-Smith W, Musto AE.Brain injuries can set up an epileptogenic neuronal network. Neurosci Biobehav Rev. 2021 Oct; 129: 351–366. DOI: 10.1016/j.neubiorev.2021.08.003. Epub 2021 Aug 9. PMID: 34384843.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Cooray GK, Rosch RE, Friston KJ. Modelling cortical network dynamics. SN Appl Sci. 2024; 6 (2): 36. DOI: 10.1007/s42452-024-05624-8. Epub 2024 Jan 29. PMID: 38299095.</mixed-citation><mixed-citation xml:lang="en">Cooray GK, Rosch RE, Friston KJ. Modelling cortical network dynamics. SN Appl Sci. 2024; 6 (2): 36. DOI: 10.1007/s42452-024-05624-8. Epub 2024 Jan 29. PMID: 38299095.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sloviter RS. Status epilepticus-induced neuronal injury and network reorganization. Epilepsia. 1999; 40 (Suppl 1): S 34–9; discussion S 40–1. DOI: 10.1111/j.1528-1157.1999.tb00876.x. PMID: 10421559.</mixed-citation><mixed-citation xml:lang="en">Sloviter RS. Status epilepticus-induced neuronal injury and network reorganization. Epilepsia. 1999; 40 (Suppl 1): S 34–9; discussion S 40–1. DOI: 10.1111/j.1528-1157.1999.tb00876.x. PMID: 10421559.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cotovio G, Oliveira-Maia AJ. Functional neuroanatomy of mania. Transl Psychiatry. 2022 Jan 24; 12 (1): 29. DOI: 10.1038/s41398-022-01786-4. PMID: 35075120.</mixed-citation><mixed-citation xml:lang="en">Cotovio G, Oliveira-Maia AJ. Functional neuroanatomy of mania. Transl Psychiatry. 2022 Jan 24; 12 (1): 29. DOI: 10.1038/s41398-022-01786-4. PMID: 35075120.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Daniels SD, Boison D. Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence.Neuropharmacology. 2023 Dec 15; 241: 109756. DOI: 10.1016/j.neuropharm.2023.109756. Epub 2023 Oct 9., PMID: 37820933.</mixed-citation><mixed-citation xml:lang="en">Daniels SD, Boison D. Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence.Neuropharmacology. 2023 Dec 15; 241: 109756. DOI: 10.1016/j.neuropharm.2023.109756. Epub 2023 Oct 9., PMID: 37820933.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Oros MM. Genetic performance criteria for valproate in patients with epilepsy. Lik Sprava. 2011 Apr-Jun; (3–4): 113–9. PMID: 2241637.</mixed-citation><mixed-citation xml:lang="en">Oros MM. Genetic performance criteria for valproate in patients with epilepsy. Lik Sprava. 2011 Apr-Jun; (3–4): 113–9. PMID: 2241637.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL. The pharmacogenomics of valproic acid. J Hum Genet. 2017 Dec; 62 (12): 1009–1014. DOI: 10.1038/jhg.2017.91. Epub 2017 Sep 7. PMID: 28878340.</mixed-citation><mixed-citation xml:lang="en">Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL. The pharmacogenomics of valproic acid. J Hum Genet. 2017 Dec; 62 (12): 1009–1014. DOI: 10.1038/jhg.2017.91. Epub 2017 Sep 7. PMID: 28878340.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ho AM, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, Nassan M, Colby CL, Larrabee BR, Weinshilboum RM, Frye MA, Biernacka JM. Mood-Stabilizing Antiepileptic Treatment Response in Bipolar Disorder: A Genome-Wide Association Study. Clin Pharmacol Ther. 2020 Dec; 108 (6): 1233–1242. DOI: 10.1002/cpt.1982. Epub 2020 Aug 7. PMID: 32627186</mixed-citation><mixed-citation xml:lang="en">Ho AM, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, Nassan M, Colby CL, Larrabee BR, Weinshilboum RM, Frye MA, Biernacka JM. Mood-Stabilizing Antiepileptic Treatment Response in Bipolar Disorder: A Genome-Wide Association Study. Clin Pharmacol Ther. 2020 Dec; 108 (6): 1233–1242. DOI: 10.1002/cpt.1982. Epub 2020 Aug 7. PMID: 32627186</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kurita M, Nishino S, Ohtomo K, Rai M, Shirakawa H, Mashiko H, Niwa S, Nakahata N. Sodium valproate at therapeutic concentrations changes Ca2+ response accompanied with its weak inhibition of protein kinase C in human astrocytoma cells. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13; 31 (3): 600–4. DOI: 10.1016/j.pnpbp.2006.11.019. Epub 2007 Jan 25. PMID: 17258372.</mixed-citation><mixed-citation xml:lang="en">Kurita M, Nishino S, Ohtomo K, Rai M, Shirakawa H, Mashiko H, Niwa S, Nakahata N. Sodium valproate at therapeutic concentrations changes Ca2+ response accompanied with its weak inhibition of protein kinase C in human astrocytoma cells. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13; 31 (3): 600–4. DOI: 10.1016/j.pnpbp.2006.11.019. Epub 2007 Jan 25. PMID: 17258372.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Akimoto T, Kusumi I, Suzuki K, Masui T, Koyama T. Effects of valproate on serotonin-induced intracellular calcium mobilization in human platelets. J. Psychiatry Neurosci. 2007 Jan; 32 (1): 17–22. PMID: 17245470.</mixed-citation><mixed-citation xml:lang="en">Akimoto T, Kusumi I, Suzuki K, Masui T, Koyama T. Effects of valproate on serotonin-induced intracellular calcium mobilization in human platelets. J. Psychiatry Neurosci. 2007 Jan; 32 (1): 17–22. PMID: 17245470.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Вовин Р. Я. Вторичная профилактика карбамазепином аффективных нарушений при эндогенных психозах // В кн.: Антиконвульсанты в психиатрической практике. С. 50–71 / под ред. А. М. Вейна, С. Н. Мосолова. Санкт-Петербург, Медицинское информационное агентство, 1994. 336 с. ISBN 5-85619-072-6.</mixed-citation><mixed-citation xml:lang="en">Vovin R. Ya. Secondary prevention of affective disorders in endogenous psychoses with carbamazepine // In the book Anticonvulsants in psychiatric practice. Pp. 50–71 / edited by A. M. Vein, S. N. Mosolov. St. Petersburg, Medical Information Agency, 1994. 336 p.  (In Russ.). ISBN 5-85619-072-6.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Мосолов С. Н., Костюкова Е. Г., Кузавкова М. В. Профилактическое применение антиконвульсантов при фазнопротекающих эндогенных психозах (сравнительное изучение карбамазепина, вальпроата натрия и солей лития) // В кн.: Антиконвульсанты в психиатрической практике. С. 72–128 / под ред. А. М. Вейна, С. Н. Мосолова. Санкт-Петербург, Медицинское информационное агентство, 1994. 336 с. ISBN 5-85619-072-6.</mixed-citation><mixed-citation xml:lang="en">Mosolov S. N., Kostyukova E. G., Kuzavkova M. V. Prophylactic use of anticonvul sants in phase-proceeding endogenous psychoses (a comparative study of carbamazepine, sodium valproate and lithium salts) // In the book Anticonvulsants in Psychiatric Practice. Pp. 72–128 / edited by A. M. Vein, S. N. Mosolov. St. Petersburg, Medical Information Agency, 1994. 336 p. (In Russ.). ISBN 5-85619-072-6.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Крыжановский Г. Н. Детерминантные структуры в патологии нервной системы. М.: Медицина, 1980. 359 с.</mixed-citation><mixed-citation xml:lang="en">Kryzhanovsky G. N. Determinant structures in the pathology of the nervous system. M.: Medicine, 1980. 359 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Strain JJ, Karim A, Caliendo G, Alexis JD, Lowe RS 3rd, Fuster V. Cardiac drug-psychotropic drug update. Gen Hosp Psychiatry. 2002 Sep-Oct; 24 (5): 283–9. DOI: 10.1016/s0163–8343(02)00184-6. PMID: 12220794.</mixed-citation><mixed-citation xml:lang="en">Strain JJ, Karim A, Caliendo G, Alexis JD, Lowe RS 3rd, Fuster V. Cardiac drug-psychotropic drug update. Gen Hosp Psychiatry. 2002 Sep-Oct; 24 (5): 283–9. DOI: 10.1016/s0163–8343(02)00184-6. PMID: 12220794.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Hollister LE, Trevino ES. Calcium channel blockers in psychiatric disorders: a review of the literature. Can J. Psychiatry. 1999 Sep; 44 (7): 658–64. DOI: 10.1177/070674379904400702. PMID: 10500866.</mixed-citation><mixed-citation xml:lang="en">Hollister LE, Trevino ES. Calcium channel blockers in psychiatric disorders: a review of the literature. Can J. Psychiatry. 1999 Sep; 44 (7): 658–64. DOI: 10.1177/070674379904400702. PMID: 10500866.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Dubovsky SL, Marshall D. Calcium Channel Antagonists for Mood Disorders. J. Clin Psychopharmacol. 2022 Mar-Apr 01; 42 (2): 188–197. DOI: 10.1097/JCP.0000000000001534. PMID: 35185116.</mixed-citation><mixed-citation xml:lang="en">Dubovsky SL, Marshall D. Calcium Channel Antagonists for Mood Disorders. J. Clin Psychopharmacol. 2022 Mar-Apr 01; 42 (2): 188–197. DOI: 10.1097/JCP.0000000000001534. PMID: 35185116.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
